(by Doug Bean | LifeSite News) – An attorney recently released data showing a remarkably high fatality rate for COVID patients who were prescribed Remdesivir.
According to attorney Thomas Renz, 25.9% of those prescribed Remdesivir for COVID-19 are recorded as having died in the Centers for Medicare & Medicaid Services (CMS) database. CMS data indicated that of 7,960 beneficiaries prescribed Remdesivir for COVID‐19, 2,058 beneficiaries died. Forty-six percent of those fatalities occurred within 14 days of Remdesivir treatment.
The death rate for COVID patients prescribed Remdesivir dwarfs the fatality rate of COVID patients prescribed Ivermectin, which is recorded by the CMS database as being 7.2%.
For the public’s further consideration of Remdesivir’s safety, Renz has pointed out that a Remdesivir Clinical Trial Final Report has shown that about a quarter of patients experienced serious adverse events from the drug. The study, published in the New England Journal of Medicine, showed that “serious adverse events were reported in 131 of the 532 patients who received Remdesivir (24.6%).”
Renz noted on his website that this data “has been withheld by the government from our citizens.” He added, “This begs the question … Why is this the protocol in American hospitals? Does this appear ‘safe and effective’ to you?”
Remdesivir is currently the only Food and Drug Administration-approved drug for the treatment of COVID-19, as the COVID-19 Treatment Guidelines Panel continues to recommend against the use of hydroxychloroquine, and will neither recommend for or against Ivermectin.
In a presentation shared on his website, Renz also pointed out that whereas hospitals will pay $390 per vial of Remdesivir, coming out to an average of $2,340 to $3,120 for a five‐day course of the drug, the average cost of Ivermectin per patient is $24.
Renz’s report of the CMS data is not the first to find a high mortality rate with the use of Remdesivir. The drug was dropped from a clinical trial for Ebola in 2018 after it was found that it had the highest death rate of the four drugs being tested, Dr. Bryan Ardis shared in a videotaped interview by an international legal group that is investigating human rights violations by governments during the COVID-19 pandemic.
The Ebola clinical trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), of which Fauci is director. As one of then-President Donald Trump’s chief medical advisers on COVID-19, he must have known that Remdesivir had a 50% death rate, compared with 35% of two other drugs in the trial – and that serious side effects, including at least one death, led to the drug being pulled and research on it abandoned.
Even as Fauci promoted the use of Remdesivir for the treatment of COVID-19 in April 2020, he admitted that “the mortality benefit of Remdesivir” had “‘not yet reached statistical significance,’” as CNBC reported.
It was after the FDA issued an Emergency Use Authorization (EUA) for the use of Remdesivir on May 1, 2020, that Ardis told the Corona Investigative Committee that America suffered the highest death rate from COVID-19 in the globe. Read Full Article >